The Scleroderma Lung Study (SLS) Investigators have published our findings in a number of leading medical journals and this work may be of interest to patients, researchers and physicians. All of our publications are cited below.

Clicking on a reference will connect you with PubMed, an online library service provided by the U.S. National Library of Medicine. PubMed will provide access to the abstract summary of the paper and, depending upon your access rights, the entire publication may be available in either HTML or PDF format.

Click here for PDF Version

Publications in chronological order:

1. Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD, Sterz MG, Chung J, FitzGerald JD, Seibold JR, Varga J, Theodore A, Wigley FM, Silver RM, Steen VD, Mayes MD, Connolly MK, Fessler BJ, Rothfield NF, Mubarak K, Molitor J, Tashkin DP; Scleroderma Lung Study Group.
Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.
Arthritis Rheum. 2005 Feb; 52(2):592-600.

2. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M; Scleroderma Lung Study Research Group.
Cyclophosphamide versus placebo in scleroderma lung disease.
N Engl J Med. 2006 Jun 22; 354(25):2655-66.

3. Cole JC, Khanna D, Clements PJ, Seibold JR, Tashkin DP, Paulus HE, Irwin MR, Motivala SJ, Furst DE on behalf of the Scleroderma Lung Study (SLS) and Relaxin Study.
Single-factor scoring validation for the Health Assessment Questionnaire-Disability Index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients.
Qual Life Res. 2006 Oct 31, 15(8):1355-1371.

4. Khanna D, Yan X, Tashkin DP, Furst DE, Elashoff R, Roth MD, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Clements PJ; Scleroderma Lung Study Group. Khanna D, Yan X, Tashkin DP, Furst DE, Elashoff R, Roth MD, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Clements PJ; Scleroderma Lung Study Group.
Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study.
Arthritis Rheum. 2007 May; 56(5):1676-84.

5. Elashoff RM, Li G, Li N.
An approach to joint analysis of longitudinal measurements and competing risks failure time data.
Stat Med 2007 Jun 30; 26(14):2813-35.

6. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, Goldin J, Arriola E, Strange C, Bolster MB, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel D, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Khanna D, Li N, Li G; Scleroderma Lung Study Research Group.
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.
Am J Respir Crit Care Med 2007 Nov 15; 176(10):1026-34.

7. Clements PJ, Roth MD, Elashoff R, Tashkin DP, Goldin J, Silver RM, Sterz M, Seibold JR, Schraufnagel D, Simms RW, Bolster M, Wise RA, Steen V, Mayes MD, Connolly K, Metersky M, Furst DE.
Scleroderma Lung Study (SLS): Differences in the presentation and course of patients with limited versus diffuse systemic sclerosis.
Ann Rheum Dis. 2007 Dec; 66(12):1641-7.

8. Strange C, Bolster MB, Roth MD, Silver RM, Theodore A, Goldin J, Clements P, Chung J, Elashoff RM, Suh R, Smith EA, Furst DE, Tashkin DP; Scleroderma Lung Study Research Group.
Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease.
Am J Respir Crit Care Med. 2008 Jan 1;177(1):91-8.

9. Kim HJ, Li G, Gjertson D, Elashoff R, Shah SK, Ochs R, Vasunilashorn F, Abtin F, Brown MS, Goldin JG.
Classification of Parenchymal Abnormality in Scleroderma Lung Using a Novel Approach to Denoise Images Collected via a Multicenter Study.
Acad Radiol. 2008 Aug;15(8):1004-16.

10. Elashoff RM, Li G, Li N.
A Joint Model for Longitudinal Measurements and Survival Data in the Presence of Multiple Failure Types.
Biometrics. 2008 Sep;64(3):762-71. Epub 2007 Dec 20.

11. Khanna D, Furst DE, Clements PJ, Tashkin DP, Eckman MH.
Oral Cyclophosphamide for Active Scleroderma Lung Disease: A Decision Analysis.
Med Decis Making. 2008 Nov-Dec;28(6):926-37. Epub 2008 Apr 28.

12. Goldin JG, Lynch DA, Strollo DC, Suh RD, Schraufnagel DE, Clements PJ, Elashoff RM, Furst DE, Vasunilashorn S, McNitt-Gray MF, Brown MS, Roth MD, Tashkin DP; for the Scleroderma Lung Study Research Group.
High-Resolution CT Scan Findings in Patients With Symptomatic Scleroderma-Related Interstitial Lung Disease.
Chest. 2008 Aug;134(2):358-367. Epub 2008 Jul 18.

13. Li N, Elashoff RM, Li G.
Robust joint modeling of longitudinal measurements and competing risks failure time data.
Biom J. 2009 Feb;51(1):19-30.

14. Hant FN, Ludwicka-Bradley A, Wang HJ, Li N, Elashoff R, Tashkin DP, Silver RM; Scleroderma Lung Study Research Group.
Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma.
J Rheumatol. 2009 Apr;36(4):773-80. Epub 2009 Mar 13.